Special Interview with Frontiers in Bioscience-Landmark Guest Editor Prof. Ralf Weiskirchen: Insights into Cellular Compartmentalization and the Journal’s Development

20 March 2026

 

 

Prof. Ralf Weiskirchen is a distinguished molecular biologist and currently serves as the Head of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry at RWTH University Hospital Aachen, Germany. His research focuses on the molecular and cellular mechanisms of liver injury and fibrosis, with particular emphasis on hepatic stellate cells, inflammatory signaling pathways, and metabolic regulation in liver disease progression. Prof. Weiskirchen is a renowned expert in liver fibrosis and cellular pathobiology, whose contributions have earned him inclusion in the Clarivate Highly Cited Researchers list for 2024 and 2025.

Recently, Prof. Weiskirchen served as the Guest Editor of the Frontiers in Bioscience-Landmark (FBL) special issue “Cellular Compartmentalization Beyond Membranes: Condensates, Contacts, and Metabolic Niches.” In this special interview, he shares insights into his academic journey, emerging concepts in cellular organization, and the future development of bioscience research.

 

Ralf Weiskirchen, PhD

RWTH University Hospital Aachen, Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), Medical Faculty, Aachen, Germany

Interests: liver diseases; hepatic fibrosis; PDGF signaling; TGF-beta signaling; cytokines and chemokines; hepatic stellate cells; gene-based biomarkers; animal models of fibrosis; LIM domain proteins; adenoviral expression technology

 

1. Could you please briefly introduce your academic background and your current main research interests?

I originally studied biology at the University of Cologne, where I also completed my PhD in molecular biology. After a postdoctoral period in Austria, I joined RWTH University Hospital Aachen, where I gradually progressed through several academic positions and eventually became the director of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry.

My research mainly focuses on the molecular and cellular mechanisms of liver injury and fibrosis. In particular, I studied the role of hepatic stellate cells, inflammatory signaling pathways, and metabolic regulation in the progression of liver disease. More broadly, my work also addresses how metabolic dysregulation contributes to the transition from fatty liver disease to hepatocellular carcinoma, as well as the general mechanisms of organ fibrosis. Over the years, I have authored around 400 original articles, 200 reviews and editorials, 42 book chapters, edited several books, including “Hepatic Stellate Cells: Methods and Protocols”, and was recently included in the 2024 and 2025 Highly Cited Researchers lists from Clarivate.

 

2. Starting from your biology studies at the University of Cologne, followed by the postdoctoral phase at the University of Innsbruck (Austria), you now serve as the Head of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry at the RWTH University Hospital Aachen. Could you share the key turning points in your academic career and how these experiences have shaped your research trajectory?

In my academic career, there have been several turning points that have been crucial in shaping my scientific trajectory. The first was my doctoral work in Cologne, where I dissected oncogene‑driven transcriptional programs in v‑myb transformed fibroblasts. This gave me a solid foundation in molecular biology and gene regulation and directed my interest toward how aberrant signaling drives diseases.

The second turning point was my postdoctoral period in Innsbruck, where I worked in an interdisciplinary environment at the Institute of Biochemistry. This broadened my expertise in how basic biochemical mechanisms translate into pathophysiology, which is extremely important.

The third and most important step was joining the RWTH University Hospital Aachen in 1999. Being embedded within an institute of clinical chemistry and pathobiochemistry moved my work closer to patients and allowed me to address clinically relevant questions in liver disease and organ fibrosis. My progression from staff member to assistant professor in 2007, acting director from 2009 to 2014, and director since 2014 gave me the opportunity to build a multidisciplinary team that combines molecular pathobiochemistry, experimental gene therapy, and clinical chemistry. My involvement in greater collaborative efforts—such as serving as scientific director and secretary of the research consortium "OrganFA," which focuses on mechanisms from injury to disease modulation, and as spokesperson for an initiative on mesenchymal interaction and metabolic injury—further shifted my focus toward integrative, systems‑level views of fibrosis and cancer development.

 

3. The special issue you curated, "Cellular Compartmentalization Beyond Membranes: Condensates, Contacts, and Metabolic Niches," aligns precisely with FBL's focus on cellular and molecular biology. How did you conceive this interdisciplinary theme? Why did you choose to focus on "membrane-less organelles" and "membrane contact sites" rather than traditional membrane-bound organelle research?

The idea for the special issue “Cellular Compartmentalization Beyond Membranes: Condensates, Contacts, and Metabolic Niches” arose from the realization that our classical view of the cell, organized mainly around membrane-bound organelles, is no longer sufficient to explain the spatial and temporal precision of many signaling and metabolic processes. Working at the interface of molecular cell biology, pathobiochemistry, and clinical hepatology has made it clear to me that dynamic, non-membranous structures, such as biomolecular condensates formed by phase separation, and membrane contact sites between organelles, are central to how cells integrate signals and adapt to stress.

Rather than adding yet another special issue on traditional organelles, I wanted to highlight these emerging concepts that cut across classical boundaries: membrane-less organelles, organelle-organelle communication, and localized “metabolic niches” where specific reactions are spatially confined and regulated.  By bringing together contributions from biophysics, cell biology, structural biology, and disease-oriented research, this special issue aims to catalyze an interdisciplinary discussion on how these non-canonical organizational principles influence cell behavior in health and disease.

 

4. This special issue emphasizes an integrated view of condensates, membrane contact sites, and metabolic niches. Why do you believe such cross-scale and cross-disciplinary integration is essential for understanding cellular function?

That's an interesting question. Understanding cellular function increasingly requires us to bridge scales—from nanometer‑level molecular interactions and mesoscale condensates to the behavior of entire cells, tissues, and organs. Biomolecular condensates, membrane contact sites, and metabolic niches are not isolated phenomena; they form an interconnected organizational network that coordinates signaling, metabolism, and organelle dynamics in space and time.

If we study condensates only as physical entities or contact sites only as structural coincidences, we miss their impact on higher‑level processes such as cell fate decisions, immune responses, or, in my case, fibrotic remodeling. Integrating across scales and disciplines—combining biophysics, quantitative cell biology, imaging, omics techniques, and computational modeling—is therefore essential to move from discrete structural descriptions to a causal understanding of how these features drive physiology and pathology.

This integrated view is particularly important for complex diseases like liver fibrosis and cancer, where deregulation at the level of molecular assemblies and organelle communication can have profound consequences at the tissue and organism level. So, you see, this is more than just a descriptive approach to addressing these topics.

 

5. As the guest editor of the FBL special issue, what specific expectations and suggestions do you have for contributing authors? For example, in terms of research design, data presentation, or academic innovation, what elements do you think are key to a successful manuscript

For contributions to this special issue, I particularly value manuscripts that are mechanistically deep, technically rigorous, and conceptually forward‑looking. In terms of research design, I encourage authors to move beyond purely descriptive observations and instead test clear, testable hypotheses about how condensates, contact sites, or metabolic niches control specific cellular functions or disease processes.

Strong quantitative data—whether from imaging, biophysical measurements, or omics—combined with appropriate statistical analysis and transparent reporting of methods and results, are crucial for reproducibility and for allowing others to build on the work. I also welcome studies that integrate multiple approaches, such as super‑resolution imaging with proteomics and functional genetics, as such combinations are often needed to convincingly link structure, composition, and function.

Finally, I look for academic innovation, which is also a new concept. New conceptual frameworks, unexpected connections between different organizational structures, or methodological advances that open up previously inaccessible aspects of cellular organization would be highly welcome in this special issue.

 

6. The special issue introduction highlights techniques such as super-resolution imaging, cryo-ET, and quantitative proteomics. Which of these—or other approaches—do you think are most likely to drive breakthroughs in the next five years?

This is always complicated to answer, but I think over the next five years, the most impactful breakthroughs will come from the integrated use of advanced imaging techniques, quantitative proteomics, and computational analysis—rather than from any single isolated technique.

Live‑cell super‑resolution microscopy and similar methods will allow us to follow the formation, dissolution, and movement of condensates and contact sites in real time, capturing dynamics that are invisible to conventional methods. Cryo‑electron microscopy and tomography, especially when combined with correlative light and electron microscopy, will be crucial for revealing the native ultrastructure of membrane contact sites at nanometer resolution under near‑physiological conditions.

Quantitative and spatially resolved proteomics—including proximity labeling, cross‑linking mass spectrometry, and organelle‑ or condensate‑specific proteomes—will help elucidate the composition and interaction networks of these structures. Importantly, artificial intelligence‑driven image analysis and integrative modeling will be essential to extract insights from the enormous multimodal datasets generated by these techniques, enabling the construction of predictive models for disease progression and cellular organization.

 

7. You have long been dedicated to research on liver fibrosis. In your view, how might new principles of cellular organization, such as 'biomolecular condensates' or 'organelle contact sites,' revolutionize our understanding of the mechanisms underlying liver diseases, like the transition from fatty liver to liver cancer that you study? Additionally, in parsing these microscopic dynamic processes, what key roles could artificial intelligence and computational models play?

I must say, having worked for many years in liver fibrosis research and related liver pathologies, including the progression from non-alcoholic fatty liver disease to hepatocellular carcinoma in many experimental models, animal models, and in vitro models, I see enormous potential for concepts like biomolecular condensates and organelle contact sites to reshape our understanding of the general disease mechanisms which are relevant in these processes.

I will give you an example: phase-separated transcriptional or signaling condensates may act as special hubs that integrate inflammatory, metabolic, and fibrogenic cues in hepatocytes and non-parenchymal cells, such as hepatic stellate cells. This may influence whether fatty liver remains stable or progresses to fibrosis or cancer. Similarly, contact sites between the endoplasmic reticulum, mitochondria, and lipid droplets are central to lipid metabolism and, of course, for calcium homeostasis and stress responses, all of which are critical in steatosis, lipotoxicity, and the resulting fibrogenesis.

So in this context, artificial intelligence and computational models can help in several ways. For example, automating the detection and quantification of condensates and contact sites in high-content imaging will allow us to better understand the processes that are going on. Building predictive models that link cellular organization to disease fate would be important. However, what is possible by these techniques, and also in pathology, and AI-based analysis of liver biopsies—which can be combined with molecular data—could reveal subtler analysis of liver biopsies and specific changes in organelle communication or condensate behavior during progression of the disease.

So I think ultimately such integrative computational-informed approaches could guide the development of therapies that target not only molecules but the physical organization and dynamic compartmentalization of the cell, and this is another approach to tackling diseases that are increasing worldwide. So I think this will be very, very important to use all these techniques.

 

8. How did you first learn about FBL? What characteristics of FBL attracted you to accept the invitation to serve as Guest Editor for this special issue?

I have been familiar with Frontiers in Bioscience-Landmark for many years because it is a venue that publishes comprehensive and often integrative work at the interface of cellular and molecular biology. When I was invited by your journal to serve as a guest editor for a special issue, I was particularly attracted by the possibility of assembling an interdisciplinary collection around a forward‑looking theme that bridges biophysics, cell biology, and disease mechanisms, and brings together many other disciplines in one special issue.

 The flexibility of FBL in supporting special issues, its broad disciplinary inclusiveness, and its openness to both mechanistic original research and in‑depth reviews made it an attractive platform to highlight emerging concepts like metabolic niches, as we are doing in our special issue. Altogether, I think FBL is well-positioned to promote this research area and foster discussion in the field.

 

9. In the current collaboration, what do you consider to be the current strengths of FBL? Looking ahead, in which areas do you think the journal could further improve or enhance to better serve researchers worldwide?

In my current collaboration with you, I see several strengths of FBL. First, I have experienced the professional handling by the editorial office—I know this because we have been in contact—and the peer review process, which is organized to be rigorous, constructive, and relatively timely. Second, the journal's scope spans cell and molecular biology with a strong emphasis on mechanistic insights, while also maintaining a clear interest in cross‑disciplinary topics. This provides an excellent platform for scholars working at the intersections of different disciplines to exchange ideas and share their work—especially for research that does not fit neatly into more narrowly defined organ‑ or technique‑specific journals.

Looking ahead, I think FBL could further enhance its impact by increasing the visibility of special issues through targeted thematic collections, social media, and cross‑promotion with related journals. Encouraging more data and code sharing practices would support reproducibility and secondary analysis. In addition, continued efforts to broaden geographical and disciplinary diversity in both the editorial board and the author landscape will help FBL better serve researchers worldwide and ensure that emerging communities and topics in the global scientific landscape are well represented.

In summary, I think you are on a good path. This journal is highly interesting for many researchers and clinicians to gain insights into disease‑related mechanisms, and in the long term, this will foster new concepts that may be relevant for developing new therapeutic targets and therapies.

 

We sincerely thank Prof. Weiskirchen for sharing his valuable time and profound insights. His dedication to advancing our understanding of cellular compartmentalization and liver disease exemplifies the mission of Frontiers in Bioscience-Landmark: to foster interdisciplinary dialogue and disseminate high-quality research that bridges fundamental biology and clinical application. We look forward to the successful completion of his special issue and the exciting discoveries it will inspire.

 

Special Issue Details: Frontiers in Bioscience-Landmark

Journal Homepage: Frontiers in Bioscience-Landmark